Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.20T
24h Vol:
$8.52B
Dominance:
MSFT:4.79%
Stocklytics Platform
Instrument logo  PRTG
Portage Biotech
PRTG
39 / 100
Penny Stock
$0.25arrow_drop_down3.81%-$0.01

Performance History

Stocklytics logo
Key Stats
Open$0.28
Prev. Close$0.26
EPS-8.52
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap6206366.00
PE Ratio-
LOWHIGH
Day Range0.22
0.42
52 Week Range0.20
4.40
Ratios
P/B Ratio0.28
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-446.02%
EBITDA Margin %-
ROE %-145.19%
EPS-8.52

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

39vs 56. Market Avg.

All Score 39 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

PRTGMARKET
Value6038
Quality2240
Ownership2117
Growth3046
Dividends-37
check_circle

Portage Biotech's Price discount from 1 year high of 92.45% is great compared to market average of 16.77%. This indicates PRTG could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$760.00
24H (%)arrow_drop_down1.49%
24H ($)-$11.54
MARKET CAP$739.19B
PRICE$512.81
24H (%)arrow_drop_up1.13%
24H ($)$5.78
MARKET CAP$453.09B
PRICE$149.91
24H (%)arrow_drop_up0.04%
24H ($)$0.06
MARKET CAP$357.92B
PRICE$130.06
24H (%)arrow_drop_down0.13%
24H ($)-$0.17
MARKET CAP$322.98B

About Portage Biotech (PRTG)

Portage Biotech Inc., together with its subsidiaries, research and develops pharmaceutical and biotechnology products. The company's product pipeline includes IMM60, an iNKT cell activator that is in phase I clinical trial; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; TT-4, an adenosine receptor type 2B (A2B) inhibitor to treat solid tumors; TT-53, an A2A/A2B inhibitor to treat solid tumors; TT-10, an adenosine receptor type 2A (A2A) inhibitor to treat A2A expressing solid tumors; TT-3, an A2B inhibitor to treat colorectal and gastrointestinal cancers; and INT230-6 for the treatment of tumors. It also provides Nanolipogel co-formulation platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products; and STING agonist platform, a proprietary immune priming and boosting technology, offers various ways to target immune stimulation towards the cancer, as well as to co-deliver various signals in a single product. The company is based in Tortola, British Virgin Islands.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Ian B. Walters M.B.A., M.D.
Headquarters
Tortola
Employees
7
Exchange
NASDAQ
add Portage Biotech to watchlist

Keep an eye on Portage Biotech

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Portage Biotech's (PRTG) price per share?

The current price per share for Portage Biotech (PRTG) is $0.25. The stock has seen a price change of -$0.01 recently, indicating a -3.82% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Portage Biotech (PRTG)?

For Portage Biotech (PRTG), the 52-week high is $4.4, which is 1.65K% from the current price. The 52-week low is $0.2, the current price is 26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Portage Biotech (PRTG) a growth stock?

Portage Biotech (PRTG) has shown an average price growth of 0.41% over the past three years. It has received a score of -2 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Portage Biotech as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Portage Biotech (PRTG) stock price performance year to date (YTD)?

As of the latest data, Portage Biotech (PRTG) has a year-to-date price change of -86.67%. Over the past month, the stock has experienced a price change of -49.6%. Over the last three months, the change has been -58.21%. Over the past six months, the figure is -79.17%.

help
Is Portage Biotech (PRTG) a profitable company?

Portage Biotech (PRTG) has a net income of -$104.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$16.58M. Furthermore, the EBITDA is -$18.93M.

help
What is the market capitalization of Portage Biotech (PRTG)?

Portage Biotech (PRTG) has a market capitalization of $6.21M. The average daily trading volume is 391.15K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.